ACE-031
Muscle In trials Human trials
Also called Ramatercept, ActRIIB-Fc
A lab-made fusion protein that joins part of the activin type IIB receptor to an antibody fragment. It works as a decoy: myostatin and related signals that hold back muscle growth bind to it instead of to muscle. It was tested in Duchenne muscular dystrophy.
Why people take it
What studies report
- Increased lean muscle mass and bone density in early human trials
- Raised muscle volume on MRI in boys with Duchenne muscular dystrophy
In practice Unapproved use
- Largely abandoned after the trial safety signal; rarely used now
Reported real-world use, not evidence and not a recommendation.
Worth knowing: Trials halted in 2011 over nosebleeds and gum bleeding from off-target effects on blood vessels.
Status: Clinical trials were stopped in 2011 after nosebleeds and gum bleeding were seen. Not approved.
- Route
- Subcutaneous injection, from reconstituted lyophilised powder
- Available as
- 1 mg
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.